Chemomab Therapeutics (CMMB) Tops Q4 EPS by 8c

Chemomab Therapeutics (NASDAQ: CMMB) reported Q4 EPS of ($0.02), $0.08 better than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Chemomab Therapeutics (CMMB) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Instil Bio Inc. (TIL) Misses Q2 EPS by 21c
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79